J.P. Morgan Maintained a Hold Rating on LifeStance Health (LFST)

LifeStance Health Group, Inc. (NASDAQ:LFST) is one of the 11 Best All-Time Low Stocks to Buy According to AnalystsOn May 28, Lisa Gill from J.P. Morgan maintained a Hold rating on LifeStance Health Group, Inc. (NASDAQ:LFST) with a price target of $8.

The company is set to release its fiscal second quarter results on August 7, 2025. Gill maintained a cautious rating despite the company’s strong performance in Q1 2025. LifeStance Health Group, Inc. (NASDAQ:LFST) delivered $333 million in revenue during the first quarter, reflecting an 11% increase and ahead of expectations by $77,190. Management noted that the number of clinicians grew 10% to 7,535, adding 152 new clinicians in the quarter, whereas the patient visit volumes also increased 10% to 2.1 million.

J.P. Morgan Maintained a Hold Rating on LifeStance Health (LFST)

A close-up of a healthcare professional studying a computer screen with data while consulting with a patient.

For full-year 2025, LifeStance Health Group, Inc. (NASDAQ:LFST) expects revenue between $1.40 billion and $1.44 billion. The company forecasts a center margin of $440 million to $464 million and adjusted EBITDA of $130 million to $150 million.

LifeStance Health Group, Inc. (NASDAQ:LFST) provides virtual and in-person outpatient mental healthcare for people of all ages. Their services include psychiatric evaluations, therapy, and testing for various mental health conditions like anxiety and depression.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.